Evaluation of three fully-automated SARS-CoV-2 antibody assays

https://doi.org/10.1515/cclm-2020-0975
Received June 24, 2020; accepted July 9, 2020; published online August 3, 2020

Abstract

Objectives: Serological assays for detection of SARS-CoV-2 antibodies are increasingly used during the COVID-19 pandemic caused by the SARS-Coronavirus-2. Here we evaluated the analytical and clinical performance of three commercially available SARS-CoV-2 antibody assays.

Methods: A total of 186 samples from 58 patients with PCR-confirmed COVID-19 infection were measured using SARS-CoV-2 antibody assays by Siemens Healthineers, Roche Diagnostics and Euroimmun. Additionally, 123 control samples, including samples collected before December 2019 and samples with potential cross-reactive antibodies were analyzed. Diagnostic specificity, sensitivity, agreement between assays and ROC curve-derived optimized thresholds were determined. Furthermore, intra- and inter-assay precision and the potential impact of interfering substances were investigated.

Results: SARS-CoV-2 antibody assays by Siemens and Roche showed 100% specificity. The Euroimmun assay had 98 and 100% specificity, when borderline results are considered as positive or negative, respectively. Diagnostic sensitivity for samples collected ≥14 days after PCR-positivity was 97.0, 89.4 and 95.5% using the Siemens, Roche and Euroimmun assay, respectively. Sensitivity of the Roche assay can be increased using an optimized cut-off index (0.095). However, a simultaneous decrease in specificity (98.4%) was observed. Siemens showed 95.8 and 95.5% overall agreement with results of Euroimmun and Roche assay, respectively. Euroimmun and Roche assay exhibited 92.6% overall agreement. Discordant results were observed in three COVID-19 patients and in one COVID-19 patient none of the investigated assays detected antibodies.

Conclusions: The investigated assays were highly specific and sensitive in detecting SARS-CoV-2 antibodies in samples obtained ≥14 days after PCR-confirmed infection. Discordant results need to be investigated in further studies.

Keywords: antibody assay; COVID-19; SARS-CoV-2; serology.

Introduction

A new disease, known as coronavirus disease 2019 (COVID-19) caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), emerged in the region of Wuhan (China) in December 2019 [1, 2]. The virus spread subsequently all over the world and the WHO officially declared the novel SARS-CoV-2 infection a pandemic. An accurate and prompt detection of SARS-CoV-2 is essential not only for the diagnosis of infected patients, but also for the establishment of infection control measures and prevention of virus spread [3, 4]. Real-time reverse transcription polymerase chain reaction (RT-PCR) using respiratory samples obtained with naso- or oropharyngeal swabs are considered as the reference method for screening and diagnosis of acute SARS-CoV-2 infection [3]. However, the sensitivity of this method may vary depending on time of sampling, the quality and origin of the sample and the viral load [5, 6]. In contrast, serologic testing of anti-SARS-CoV-2 antibodies (IgG, IgM and IgA) can be easily performed by using venous blood samples. SARS-CoV-2 antibody assays are proposed to play an important role in diagnosis of
COVID-19 convalescents and in patients with clinical symptoms suggestive for SARS-CoV-2 infection but with negative or not available RT-PCR results [4]. Furthermore, antibody assays may help to understand the epidemiology of SARS-CoV-2 infections, support the selection of convalescent plasma for therapeutic treatments and potentially to evaluate the efficiency of future vaccines [7, 8].

Numerous SARS-CoV-2 antibody assays have been approved including lateral flow tests, enzyme-linked immunosorbsorbent assays (ELISA) and fully-automated electrochemiluminescent (ECLIA) or chemiluminescent immunosassays (CLIA). Due to the increasing numbers of these serological tests, the lack of comparative data in combination with the high demand on serological assays it is essential for laboratory professionals to carefully evaluate SARS-CoV-2 antibody assays. Therefore, the aim of this study was to compare the clinical and analytical performance of three commercially available, fully-automated ELISA-, CLIA- and ECLIA-based SARS-CoV-2 antibody assays. To date, this is the first evaluation of the Siemens SARS-CoV-2 antibody assay.

### Material and methods

#### Study

The study was conducted as part of the diagnostic evaluation of SARS-CoV-2 serologic testing for routine use at the Institute for Clinical Chemistry and Pathobiochemistry at the University Hospital Tübingen according to the declaration of Helsinki of 1964 and its later amendments in accordance with the local Ethics Committee of the University of Tübingen. Routine blood samples (n=186) of hospitalized COVID-19 patients (n=58) were used for serial antibody measurements. COVID-19 diagnosis was based on detection of SARS-CoV-2-RNA in oro- and/or nasopharyngeal swab by RT-PCR. Median time between positive PCR result and blood sample collection was 19 days (interquartile range: 12–29 days). COVID-19 negative control samples were all obtained before the beginning of the pandemic and comprises intensive care patients (n=88). In addition, potential cross-reactive antibodies (n=35) were investigated using samples from patients with laboratory confirmed acute infections with influenza A virus (n=5), human respiratory syncytial virus (n=1) and common cold coronaviruses (NL63: n=1; Hoku-1 + NL63: n=1; NL63 + 229E: n=1). Furthermore, samples with IgM antibodies against human cytomegalovirus (n=5) and varicella zoster virus (n=2), samples from patients with respiratory symptoms not suspicious of COVID-19 disease (n=11), samples containing antibodies (n=6) against chlamydia pneumoniae (IgG, IgA and/or IgM) or candida albicans (IgG and/or IgA) and samples positive for rheumatoid factor (n=2) were included in the study.

#### Assessment of analytical performance

Intra- and inter-assay precision was determined using quality control samples, if provided by the manufacturer, or antibody positive and negative patient samples. Intra- and inter-assay precision was determined from serial measurements (n=10) and measurements of quintuplicates during five consecutive days according to the Clinical and Laboratory Standards Institute (CLSI) EP15-A3 protocol [9]. For interference testing hemolytic (n=6), icteric (n=6) and lipemic (n=6) samples were spiked with plasma from highly SARS-CoV-2 antibody positive samples. Concentrations of plasma hemoglobin, triglycerides and total bilirubin were determined using photometric and enzymatic methods on a Dimension Vista and ADVIA Clinical chemistry XPT, respectively. Furthermore, potential interference of biotin was assessed using SARS-CoV-2 antibody positive and negative samples that were spiked with biotin (final concentrations of biotin: 1,000, 1,500 and 2,000 ng/mL).

#### Laboratory measurements

SARS-CoV-2 specific antibodies were detected according to the manufacturer’s instructions on three different automated platforms.

### Table 1: Characteristics of three SARS-CoV-2 antibody assays investigated in the present study as given by the manufacturers.

| Manufacturer | Elicys anti-SARS-CoV-2 | SARS-CoV-2 Total (COV2T) |
|--------------|------------------------|--------------------------|
| Euroimmun    |                        |                          |
| Method       | ELISA                  | ECLIA                    | Siemens Healthineers |
| Detection    | IgG antibodies         | Antibodies (including IgG) |                  |
| Antigen target | S1 spike protein      | Nucleocapsid protein     |                |
| Results      | Ratio                  | Cut-off index            |                |
| Interpretation | <0.8: negative         | <1.0 negative            |                |
|              | 0.8 – <1.1: borderline | ≥1.0 positive            |                |
|              | ≥1.1: positive         |                          |                |
| Specificity  | 99.3%                  | 99.8%                    | 99.8%          |
| Sensitivity (days after PCR-positivity) | ≤10: 22.4% | 0–6: 65.5% | 0–6: 61.1% |
|              | 11–20: 87.5%           | 7–13: 88.1%              | 7–13: 97.5%    |
|              | ≥20: 100%              | ≥14: 100%                | ≥14: 100%      |
| Platform     | BEP 2000 Advance       | Cobas e411               | ADVIA Centaur XPT |

ELISA, enzyme-linked immunosorbsorbent assay; ECLIA, electrochemiluminescence immunoassay; CLIA, chemiluminescence immunoassay.
Results

Specificity, sensitivity and agreement of the three serological assays

To evaluate the diagnostic specificity of SARS-CoV-2 antibody assays we used control samples of patients collected before December 2019, which were considered true negative. The specificity of the Siemens and Roche assays was 100% (Table 2). Moreover, analysis of samples from patients with other acute viral and bacterial or fungal infections showed no cross-reactivity using these two assays. The Euroimmun assay showed 98% specificity using the same samples, when borderline results were considered positive. However, when borderline results were considered negative, the Euroimmun assay exhibited 100% specificity as well. False positive results were not detected by the Euroimmun assay. Borderline results were observed for samples from two patients with acute influenza A virus infection and from one patient with infection of coronaviruses HKU-1 and NL63.

Diagnostic sensitivity was determined using samples from patients with RT-PCR confirmed COVID-19 disease at different time points. Sensitivity of the Siemens assay was 56.5% in the first six days after PCR positive SARS-CoV-2 result, 90.3% at days 7–13 and 97.0% at day 14 or later (Table 3). The Roche assay revealed a diagnostic sensitivity of 65.2% in the first six days after PCR positive SARS-CoV-2 result, 90.3% at days 7–13 and 89.4% at day 14 or later. Diagnostic sensitivity of the Euroimmun assay was 47.8% in the first six days, 83.9% at days 7–13 and 95.5% at day 14 or later, if borderline results were considered negative. Considering borderline results as positive, diagnostic sensitivity in the first six days changed to 56.5%. Sensitivity for the other sampling time points remained unchanged. No further borderline results were detected by the Euroimmun assay.

### Table 2: Specificity of SARS-CoV-2 antibody assays.

|                | Siemens | Roche | Euroimmun |
|----------------|---------|-------|-----------|
|               | IgG     | IgG   | IgG       |
| Before Dec 2019| 0/88    | 0/88  | 0/88      |
| Coronavirus (HKU-1, NL63, 229E) | 0/3 | 0/3 | 0/3 (1/3)* |
| Influenza A virus | 0/5 | 0/5 | 0/5 (2/5)* |
| CMV IgM        | 0/5     | 0/5   | 0/5       |
| VZV IgM        | 0/2     | 0/2   | 0/2       |
| RSV           | 0/1     | 0/1   | 0/1       |
| Rheumatoid factor | 0/2 | 0/2 | 0/2       |
| Respiratory Panel* | 0/6 | 0/6 | 0/6       |
| Negative serology* | 0/11 | 0/11 | 0/11     |
| Positive serology* | 0/123 | 0/123 | 0/123 (3/123)* |
| Total specificity | 100% | 100% | 100% (98%)* |

*If borderline results were considered positive.

### Table 3: Sensitivity of SARS-CoV-2 antibody assays.

| Time from PCR+ | Siemens | Roche | Euroimmun |
|----------------|---------|-------|-----------|
| 0–6 days (n=23) | 56.5%   | 65.2% | 47.8%     |
| (13/23)        | (15/23) | (11/23)|          |
| 7–13 days (n=31) | 90.3% | 90.3% | 83.9%     |
| (28/31)        | (28/31) | (26/31)|          |
| ≥14 days (n=132) | 97.0% | 89.4% | 95.5%     |
| (128/132)      | (118/132)| (126/132)|        |

*If borderline results were considered positive; PCR+: positive RT-PCR SARS-CoV-2 result.
Comparing qualitative results of SARS-CoV-2 antibody assays, the Siemens assay showed an overall percent agreement of 95.5% (Cohen’s Kappa 0.91, CI: 0.86–0.96) with the Roche assay. The Euroimmun assay had an overall agreement of 95.8% (Cohen’s Kappa 0.92, CI: 0.87–0.96) and 97.4% (Cohen’s Kappa 0.95, CI: 0.91–0.98) with the Siemens assay, when borderline results were considered positive or negative, respectively (Table 4). The Roche assay and Euroimmun assay showed an overall percent agreement of 92.6% (Cohen’s Kappa 0.88, CI: 0.83–0.94) when borderline results were considered positive or negative, respectively. Discordant results can be assigned to three PCR-confirmed COVID-19 patients. Moreover, in another PCR-confirmed COVID-19 patient none of the investigated assays detected antibodies in serial blood samples obtained until 18 days after PCR positivity.
Receiver operating characteristic (ROC) curve analysis

ROC curve analyses revealed areas under the curves (AUC) >0.93 for all three assays (Siemens: 0.971, Roche: 0.953, Euroimmun: 0.937; Figure 1). Based on ROC curves optimized cut-off indices were derived. We found optimal decision thresholds for cut-off indices of >0.75, >0.095 and >0.958 for the Siemens, Roche and Euroimmun assay, respectively (Table 5). Applying these thresholds the sensitivity at day ≥14 after PCR-positivity of the Roche assay improved (97.0 vs. 89.4%). However, at the same time, the specificity decreased to 98.4%, because two samples collected before December 2019 were identified as false positive (COI 0.530 and 0.500). The Siemens assay showed slightly improved sensitivity in the first 6 days after PCR-positivity (60.9 vs. 56.5%). Sensitivity for samples collected >6 days and specificity of the Siemens assay were unaffected. Using the single cut-off index for the Euroimmun assay sensitivities remained unchanged but specificity improved to 100%.

Intra-and inter-assay precision and assessment of analytical interferences

Determination of intra- and inter-assay precision revealed coefficient of variations between 2.6–11.3 and 4.9–17.1% for the investigated assays using quality control samples provided by the manufacturers or antibody positive and negative patient samples (Supplemental Table 1 and 2). Potential analytical interferences by increased plasma hemoglobin (hemolysis), total bilirubin (icterus) or triglyceride (lipemia) concentrations were negligible (Supplemental Table 3). Biotin spiking (final concentrations ≤2000 ng/mL) of plasma samples of SARS-CoV-2 antibody negative and positive samples showed no significant impact on antibody results using all three serological assays.

Discussion

The present study evaluated and compared three SARS-CoV-2 antibody assays by Siemens Healthineers, Roche Diagnostics and Euroimmun which were run on fully-automated platforms. To date, this is the first evaluation of the Siemens SARS-CoV-2 antibody assay. All three assays demonstrated high diagnostic specificity. Only the Euroimmun assay detected three false borderline results. The Siemens assay was found to be slightly more sensitive than the Roche and Euroimmun assays but none of these assays was sufficiently sensitive to safely detect antibodies <14 days after PCR-confirmed SARS-CoV-2 infection.
High diagnostic specificity is crucial to reduce the number of false positive results in serological testing. The Roche and Siemens assays demonstrated 100% specificity in samples collected before December 2019 when the virus was not present in Germany and in samples with potential cross-reactive antibodies from acute viral and bacterial or fungal infections. Only in the case of the Euroimmun assay three false borderline results were observed, which were found in two samples with influenza A virus and in one sample with other coronaviruses (HKU-1 and NL63). The specificities of the Roche and Euroimmun assays are similar to those given by the manufacturers and other recent studies [10–14]. Some reports showed slightly reduced specificities (>96%) for the Euroimmun assay [15, 16]. Specificity of the Roche assay was demonstrated as >98–100% in three other reports [10–12]. However, specificities between studies are difficult to compare due to different numbers and origins of samples used for the evaluations. Although serological assays exhibit high diagnostic specificity and sensitivity (>99%), the positive predictive value of a single test can be markedly reduced in populations with low prevalence of SARS-CoV-2 [7]. This should be taken into account when evaluating antibody screening studies.

Regarding the diagnostic sensitivity, results of all three assays were similar in the early phase of the SARS-CoV-2 infection (<7 days after PCR-positivity). Sensitivities varied between 47.8 and 65.2% and were not sufficient for detection of acute SARS-CoV-2 infections. This is in accordance with studies using comparative commercially available SARS-CoV-2 antibody assays showing insufficient diagnostic sensitivity in the early phase (<7 days) after symptom onset [10–14, 16–18]. With progression of disease the sensitivities of all three assays markedly increased. Considering samples collected >14 days after PCR-positivity, the Siemens assay showed higher sensitivity (97.0%) in comparison to the Euroimmun (95.5%) and the Roche (89.4%) assay. These results contradict the information provided by the manufacturers claiming 100% sensitivity for samples obtained >14 days after PCR-positivity. Other studies reported sensitivities between 89 and 100% using the Euroimmun and Roche assay for samples collected >14 days after PCR-positivity. The Euroimmun additionally offers an Anti-SARS-CoV-2-ELISA for the detection of IgA antibodies which may increase the sensitivity in the early phase according to the manufacturer and to recent publication [19]. However, the performance analysis of this assay was not in the scope of the study.

Although the majority of patients showed comparable and plausible results in the investigated assays, exceptional cases were observed. One PCR positive patient was antibody negative (confirmed in follow-up measurements) when tested with all three assays and remained negative even when applying the optimized cut-off indices presented in this study. Moreover, in two patients with positive PCR the Roche or Euroimmun assay failed to detect antibodies. Using the optimized cut-off indices, results by the Roche assay become positive whereas results by the Euroimmun assay remain negative. The use of optimized thresholds was recently highlighted by some other studies [12, 15, 18]. In accordance with our results, a lower cut-off index was proposed for the Roche assay and also for other SARS-CoV-2 antibody assays optimized cut-off indices have been proposed. In our study, the optimized cut-off indices for the Siemens and Euroimmun assay only slightly improved the performance of these assays. Larger studies are needed to reevaluate modified thresholds.

The main explanation for discordant results may be the use of different antigen targets and detection of different antibody classes by the assays used in our study. The Roche assay targets the nucleocapsid of the SARS-CoV-2 virus and detects total antibodies (including IgG), the Euroimmun assay targets the S1 domain of the spike protein and detects IgG antibodies, whereas the Siemens assay detects total antibodies (IgG and IgM) against the receptor binding domain (RBD) of the S1 protein. Therefore, discordant results are likely to be expected. Recent data suggest that the RBD domain, besides other parts of the S protein, is a potent target for neutralizing antibodies. Thus, these may be promising target structures for the design of therapeutic antibodies and future vaccines [20–22]. Although neutralizing antibodies have been described in COVID-19 convalescents, there are no definitive data available regarding antibody results by commercially available antibody assays and protective immunity [3, 23]. Moreover it is interesting to note, that in one further COVID-19 patient the antibody ratio decreased over time using the Roche assay and became negative in samples >28 days using the manufacturer’s cut-off index whereas the Siemens and Euroimmun antibody ratio did not decrease. Decreased antibody ratio with time was recently demonstrated in a patient with chronic lymphatic leukemia and also in another evaluation decreased antibody ratio with time was shown in several patients using the Roche assay [11, 24]. However, no pre-existing conditions were known for our patient. Since Roche declares that mainly high-affinity antibodies are detected in their assay, it is speculated that this may explain the decrease in antibody ratio with time [11]. Important to note, results of the Roche assay remain positive when applying the optimized cut-off index presented in the study. Finally, to elucidate whether the decrease in antibody ratio is an analytical issue or whether
special parts of antibodies may disappear after time needs to be elucidated in long-term follow-up antibody studies.

A limitation of the study includes that sensitivity of the investigated assays was based on time from PCR-positivity and therefore may be overestimated for the earlier time points due to potentially delayed PCR diagnostic. Most of the patients were critically ill and treated on the intensive care unit, therefore precise data regarding the time of symptoms onset was not available in the majority of these patients. However, results were compared to manufacturers’ claims reporting diagnostic sensitivities based on time from PCR-positivity as well (Table 1). Furthermore, in a study comparing sensitivities of two serological SARS-CoV-2 antibody assays between time from symptom onset and time from PCR-positivity similar results were found for samples obtained at 14 days or later [25].

In conclusion, the investigated assays by Siemens Healthineers, Roche Diagnostics and Euroimmun are all highly specific and sensitive serologic assays for the detection of antibodies against SARS-CoV-2. Highest sensitivity of antibody detection was observed in samples >14 days after PCR-positivity. In addition, in a low percentage of all samples discordant results were observed which are likely due to the different antigen targets of the investigated assays.

Acknowledgements: We thank Isolde Riedlinger for excellent technical assistance.

Research funding: None declared.

Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.

Competing interests: Authors state no conflict of interest.

Ethical approval: This study complied with all relevant national regulations, institutional policies and is in accordance with the tenets of the Helsinki Declaration (as revised in 2013), and has been approved by local Ethics Committee.

References

1. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020;579:270–3.
2. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020;382:727–33.
3. Bohn MK, Lippi G, Horvath A, Sethi S, Koch D, Ferrari M, et al. Molecular, serological, and biochemical diagnosis and monitoring of COVID-19: IFCC taskforce evaluation of the latest evidence. Clin Chem Lab Med 2020;58:1037–52.
4. Sethuraman N, Jeremiah SS, Ryo A. Interpreting diagnostic tests for SARS-CoV-2. J Am Med Assoc 2020. https://doi.org/10.1001/jama.2020.8259.
5. Loeffelholz MJ, Tang YW. Laboratory diagnosis of emerging human coronavirus infections - the state of the art. Emerg Microb Infect 2020;9:747–56.
6. Lippi G, Simundic AM, Plebani M. Potential preanalytical and analytical vulnerabilities in the laboratory diagnosis of coronavirus disease 2019 (COVID-19). Clin Chem Lab Med 2020;58:1070–6.
7. Farnsworth CW, Anderson NW. SARS-CoV-2 serology: much hype, little data. Clin Chem 2020;66:875–7.
8. Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. J Am Med Assoc 2020. https://doi.org/10.1001/jama.2020.4783.
9. Clinical and Laboratory Standards Institute (CLSI). User verification of precision and estimation of bias: Approved Guideline, 3rd Edn. CLSI EP15-A3; 2014.
10. Egger M, Bundschuh C, Wiesinger K, Gabriel C, Clodi M, Mueller T, et al. Comparison of the Elecsys(R) Anti-SARS-CoV-2 immunoassay with the EI enzyme linked immunosorbent assays for the detection of SARS-CoV-2 antibodies in human plasma. Clin Chim Acta 2020;509:18–21.
11. Tang MS, Hock KG, Logsdon NM, Hayes JE, Gronowski AM, Anderson NW, et al. Clinical performance of the Roche SARS-CoV-2 serologic assay. Clin Chem 2020. https://doi.org/10.1093/clinchem/hva132.
12. Favresse J, Eucher C, Elsen M, Marie TH, Dogne JM, Douxfils J. Clinical performance of the Elecsys electrochemiluminescent immunoassay for the detection of SARS-CoV-2 total antibodies. Clin Chem 2020. https://doi.org/10.1093/clinchem/hvaa131.
13. Montesinos I, Gruson D, Kabamba B, Dahma H, Van den Wijngaert S, Reza S, et al. Evaluation of two automated and three rapid lateral flow immunoassays for the detection of anti-SARS-CoV-2 antibodies. J Clin Virol 2020;128:104413.
14. Theel ES, Harring J, Hilgart H, Granger D. Performance characteristics of four high-throughput immunoassays for detection of IgG antibodies against SARS-CoV-2. J Clin Microbiol 2020. https://doi.org/10.1128/JCM.01243-20.
15. Tre-Hardy M, Wilmet A, Beukinga I, Dogne JM, Douxfils J, Blairon L. Validation of a chemiluminescent assay for specific SARS-CoV-2 antibody. Clin Chem Lab Med 2020;8:1357–64.
16. Van Elslande J, Houben E, Depypere M, Brackenier A, Desmet S, Andre E, et al. Diagnostic performance of seven rapid IgG/IgM antibody tests and the Euroimmun IgA/IgG ELISA in COVID-19 patients. Clin Microbiol Infect 2020. https://doi.org/10.1016/j. cmi.2020.05.023.
17. Jaaskelainen AJ, Kuivanen S, Kekalainen E, Ahava MJ, Loginnov R, Kallio-Kokko H, et al. Performance of six SARS-CoV-2 immunoassays in comparison with microneutralisation. J Clin Virol 2020;129:104512.
18. Plebani M, Padoan A, Negrini D, Carpinteri B, Sciacovelli L. Diagnostic performances and thresholds: the key to harmonization in serological SARS-CoV-2 assays?. Clin Chim Acta 2020;509:1–7.
19. Jaaskelainen AJ, Kekalainen E, Kallio-Kokko H, Mannonen L, Kortela E, Vapalahti O, et al. Evaluation of commercial and automated SARS-CoV-2 IgG and IgA ELISAs using coronavirus disease (COVID-19) patient samples. Euro
Rogers TF, Zhao F, Huang D, Beutler N, Burns A, He WT, et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv; 2020. https://doi.org/10.1101/2020.05.11.088674.

Brouwer PJM, Caniels TG, van der Straten K, Snitselaar JL, Aldon Y, Bangaru S, et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. Science 2020. https://doi.org/10.1126/science.abc5902.

Wec AZ, Wrapp D, Herbert AS, Maurer DP, Haslwanter D, Sakharkar M, et al. Broad neutralization of SARS-related viruses by human monoclonal antibodies. Science 2020. https://doi.org/10.1126/science.abc7424.

Jiang S, Hillyer C, Du L. Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses. Trends Immunol 2020; 41:545.

Favresse J, Eucher C, Elsen M, Graux C, Goebels P, Laffineur K, et al. Unexpected kinetics of anti-SARS-CoV-2 total antibodies in two patients with chronic lymphocytic leukemia. Br J Haematol 2020. https://doi.org/10.1111/bjh.16954.

Tang MS, Hock KG, Logsdon NM, Hayes JE, Gronowski AM, Anderson NW, et al. Clinical performance of two SARS-CoV-2 serologic assays. Clin Chem 2020. https://doi.org/10.1093/clinchem/hvaa120.

Supplementary material: The online version of this article offers supplementary material (https://doi.org/10.1515/cclm-2020-0975).